The research will help Mayo Clinic and Ultromics jointly develop an image analysis application to pinpoint the novel cardiac features of COVID-19 and help physicians more quickly triage and treat high-risk patients, according to a news release emailed to Becker’s Hospital Review.
The multi-site study will analyze echocardiography exams over a three-month period of 500 COVID-19 positive men and women, ages 18-89. Researchers are primarily interested in assessing automated cardiac measurements and ejection fraction, or the percentage of how much blood the heart’s left ventricle pumps with each contraction, to classify COVID-19 patient outcomes.
More articles on artificial intelligence:
AI can categorize lung nodules’ cancer risk, study suggests
Some physicians apprehensive about AI’s ability to diagnose COVID-19
AI spots potential COVID-19 treatment drug within two days
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
